Finalists revealed for CPhI Pharma Awards

The finalists for the CPhI Pharma Awards at the forthcoming CPhI Worldwide event have been announced.

The shortlist spans thirteen different award categories covering the full spectrum of the pharmaceutical supply chain – including ‘Formulation’, ‘Packaging’ and ‘Lifetime Achievement Awards’.

The winners will be announced on November 5 at a ceremony in The Forum, Congress Centre Messe Frankfurt.

This year’s judging panel – comprised of independent, senior industry experts – have carefully selected the finalists from all the received entries.

Subsequently, the winners’ shortlist is packed with forty of the industry’s most innovative companies and individuals who are truly shaping the future of pharma.

Since 2003, the CPhI Pharma Awards, powered by Informa Pharma Intelligence have focused on recognising innovation in the pharmaceutical industry, applauding pharmaceutical and biopharmaceutical companies engaged in the design, development, manufacture, production and distribution of large and small molecule drug products.

This year, the formulation and packaging categories were the most competitive, with both accolades boasting seven finalists each.

“This year has been a truly ground-breaking year for innovation in the pharmaceutical industry as demonstrated by the quality of the entries for the CPhI Pharma Awards covering all parts of the pharmaceutical supply chain,” said Tara Dougal, Head of Content at Informa.

“The judges have tirelessly worked to ensure that all award submissions and their merits were thoroughly evaluated, and I’d like to thank them for all their efforts.

“Good luck to the finalists and I look forward to seeing many of them at the Awards ceremony on the opening day of CPhI Worldwide.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Intravacc & Celonic to develop, produce novel COVID-19 vaccine

Intravacc, a Dutch viral and bacterial vaccine specialist, and Swiss CDMO, Celonic Group, have signed a research agreement to further design, develop and produce...

Tecentriq combination approved for advanced melanoma

The FDA has approved Roche’s Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients. The safety...

European approval for Novartis’ Cosentyx in paediatric psoriasis

Novartis has gained European approval for Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6 to <18 years. The...

Hetero cleared to launch first remdesivir generic in India

Hetero, one of India’s leading generic pharmaceutical companies, has received the manufacturing and marketing approval for remdesivir from the Drug Controller General of India...

Collaboration to develop stem cell therapies for COVID-19 and future pandemic diseases

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, has expanded its collaboration and license agreement with Daewoong Pharmaceutical Co. Ltd. and AffyXell...

Related news

In brief: Sanofi & GSK in talks to supply 300m doses of COVID vaccine to EU

Sanofi and GlaxoSmithKline (GSK) are in “advanced discussions” with the European Commission (EC) for the supply of up to 300 million doses of a...

Intravacc & Celonic to develop, produce novel COVID-19 vaccine

Intravacc, a Dutch viral and bacterial vaccine specialist, and Swiss CDMO, Celonic Group, have signed a research agreement to further design, develop and produce...

Tecentriq combination approved for advanced melanoma

The FDA has approved Roche’s Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients. The safety...

European approval for Novartis’ Cosentyx in paediatric psoriasis

Novartis has gained European approval for Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6 to <18 years. The...